Ryman Healthcare (RYM) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
26 May, 2026Executive summary
Net profit after tax fell 50% to $94.4 million for the six months ended 30 September 2024, with negative cash flow from existing operations and a renewed board and executive team, including a new CEO and functional structure.
Revenue rose 10% year-over-year to $366.3 million, driven by increased care and village fees, new openings, and higher deferred management fees.
Significant business improvement initiatives delivered $18 million in annualised savings, with further cost reductions targeted and a new pricing structure launched.
Major accounting policy changes and restatements were implemented for greater transparency and comparability, including DMF revenue recognition and reclassification of development land.
No interim dividend declared; dividend policy to be reviewed in FY26.
Financial highlights
Net profit before tax and fair value movements was a loss of $79.8 million, down year-over-year; net profit after tax was $94.4 million, down 50% from $187.1 million.
Revenue rose to $366.3 million, up 10% year-over-year, while operating expenses increased 18% to $351.7 million.
Cash flow from existing operations was -$7.8 million, down $24.8 million year-over-year; cash flow from development improved to -$44.7 million, a $132 million improvement.
Gross receipts from ORA sales reached $651.4 million, up 5% year-over-year; gross resale margin compressed to 26.6%.
Net interest-bearing debt at period end was $2.56 billion, with gearing at 37.3%.
Outlook and guidance
Free cash flow for FY25 now expected to be negative $50–100 million, revised from previous positive guidance, as settlements are deferred into FY26.
Capital expenditure guidance reduced to $625–675 million.
Delivery/build rate of retirement units and aged care beds expected at the top end of 850–950.
Further business improvement savings targeted by end of FY26.
Challenging economic and housing market conditions in New Zealand and Victoria expected to persist, impacting settlements and margins.
Latest events from Ryman Healthcare
- Secured 6-year bond offer supports refinancing and growth, leveraging strong financials.RYM
Investor presentation8 Jun 2026 - First positive free cash flow in a decade, higher revenue, and raised FY26 guidance amid sector reforms.RYM
H1 202626 May 2026 - Operating EBITDAF nearly doubled and free cash flow turned positive, supporting strategic progress.RYM
H2 202626 May 2026 - $1.0b equity raise reduces debt and enables transformation, targeting sustainable growth.RYM
Investor presentation14 May 2026 - Targeting NZD 150m cash flow uplift and NZD 500m cash release by FY 2029, with resumed dividends.RYM
Investor Day 20264 Feb 2026 - Strategic reset, board overhaul, and $1B equity raise drive focus on value recovery.RYM
AGM 20253 Feb 2026 - Cash flow up, profit down, dividends suspended, new villages opened, sector funding tight.RYM
AGM 20242 Feb 2026 - Record build, improved cash flow, and cost savings set up for disciplined FY26 growth.RYM
H2 202520 Nov 2025